Want to join the conversation?
$AVGO, which competes with $ADI and $FNSR, said that 1Q16 GM from continuing operations was 61%, which was at the midpoint of the guidance range. R&D expense was $238MM and SG&A expense was $68MM resulting in total OpEx of $306MM, $8MM below guidance. Percentage-wise, total OpEx was 17% of revenue.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)